Shin, A. E., Sugiura, K., Kariuki, S. W., Cohen, D. A., Flashner, S. P., Klein-Szanto, A. J., Nishiwaki, N., De, D., Vasan, N., Gabre, J. T., Lengner, C. J., Sims, P. A., & Rustgi, A. K. (2025). LIN28B-mediated PI3K/AKT pathway activation promotes metastasis in colorectal cancer models. Journal of Clinical Investigation. https://doi.org/10.1172/jci186035

Shah, N. N., Wang, M., Roeker, L. E., Patel, K., Woyach, J. A., Wierda, W. G., Ujjani, C. S., Eyre, T. A., Inzani, P. L. Z., Alencar, A. J., Ghia, P., Lamanna, N., Hoffmann, M. S., Patel, M. R., Flinn, I., Gerson, J. N., Ma, S., Coombs, C. C., Cheah, C. Y., … Brown, J. R. (2024). Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial. Haematologica. https://doi.org/10.3324/haematol.2024.285754

Lamanna, N., Tam, C. S., Woyach, J. A., Alencar, A. J., Palomba, M. L., Zinzani, P. L., Flinn, I. W., Fakhri, B., Cohen, J. B., Kontos, A., Konig, H., Ruppert, A. S., Chatterjee, A., Sizelove, R., Compte, L., Tsai, D. E., & Jurczak, W. (2024). Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy. EJHaem, 5(5), 929–939. Portico. https://doi.org/10.1002/jha2.1013

Zhang, F., Sahu, V., Peng, K., Wang, Y., Li, T., Bala, P., Aitymbayev, D., Sahgal, P., Schaefer, A., Der, C. J., Ryeom, S., Yoon, S., Sethi, N., Bass, A. J., & Zhang, H. (2024). Recurrent RhoGAP gene fusion CLDN18-ARHGAP26 promotes RHOA activation and focal adhesion kinase and YAP-TEAD signalling in diffuse gastric cancer. Gut, 73(8), 1280–1291. https://doi.org/10.1136/gutjnl-2023-329686

Gbadegesin, R., Martinelli, E., Gupta, Y., Friedman, D. J., Sampson, M. G., Pollak, M. R., & Sanna-Cherchi, S. (2024). APOL1 genotyping is incomplete without testing for the protective M1 modifier p.N264K variant. Glomerular Diseases. Portico. https://doi.org/10.1159/000537948

Hijiya, N., Maschan, A., Rizzari, C., Shimada, H., Dufour, C., Goto, H., Kang, H. J., Guinipero, T., Karakas, Z., Bautista, F., Ducassou, S., Yoo, K. H., Zwaan, C. M., Millot, F., Patterson, B. C., Samis, J., Izquierdo, M., Titorenko, K., Li, S., & Sosothikul, D. (2023). The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study. Blood Advances, 7(23), 7279–7289. https://doi.org/10.1182/bloodadvances.2023010122

Le, X., Patel, J., Shum, E., Sanborn, R. E., Baik, C. S., Shu, C. A., Kim, C., Fidler, M. D., Hall, R., Hanna, N., Mohindra, N., Sabari, J. K., Heeke, S., Hernandez, M., Gray, J. E., Heymach, J. V., & Saltos, A. (2023). LBA71 A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis). Annals of Oncology, 34, S1313–S1314. https://doi.org/10.1016/j.annonc.2023.10.072

Lamanna, N., Tam, C., Jurczak, W., Kontos, A., Konig, H., Ruppert, A., Tsai, D., & Scheliga, A. (2023). COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS. Hematology, Transfusion and Cell Therapy, 45, S161. https://doi.org/10.1016/j.htct.2023.09.359

Thummalapalli, R., Bernstein, E., Herzberg, B., Li, B. T., Iqbal, A., Preeshagul, I., Santini, F. C., Eng, J., Ladanyi, M., Yang, S.-R., Shen, R., Lito, P., Riely, G. J., Sabari, J. K., & Arbour, K. C. (2023). Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non–Small Cell Lung Cancer. JCO Precision Oncology, 7. https://doi.org/10.1200/po.23.00030

Sivakumar, S., Jin, D. X., Rathod, R., Ross, J., Cantley, L. C., Scaltriti, M., Chen, J. W., Hutchinson, K. E., Wilson, T. R., Sokol, E. S., & Vasan, N. (2023). Genetic Heterogeneity and Tissue-specific Patterns of Tumors with MultiplePIK3CAMutations. Clinical Cancer Research, 29(6), 1125–1136. https://doi.org/10.1158/1078-0432.ccr-22-2270

Li, T., Kikuchi, O., Zhou, J., Wang, Y., Pokharel, B., Bastl, K., Gokhale, P., Knott, A., Zhang, Y., Doench, J. G., Ho, Z. V., Catenacci, D. V. T., & Bass, A. J. (2023). Developing SHP2-based combination therapy for KRAS-amplified cancer. JCI Insight, 8(3). https://doi.org/10.1172/jci.insight.152714

Ilozumba, M. N., Yao, S., Llanos, A. A. M., Omilian, A. R., Zhang, W., Datta, S., Hong, C.-C., Davis, W., Khoury, T., Bandera, E. V., Higgins, M., Ambrosone, C. B., & Cheng, T.-Y. D. (2022). mTOR pathway gene expression in association with race and clinicopathological characteristics in Black and White breast cancer patients. Discover Oncology, 13(1). https://doi.org/10.1007/s12672-022-00497-y

Wang, Y., Spolitu, S., Zadroga, J. A., Sarecha, A. K., & Ozcan, L. (2022). Hepatocyte Rap1a contributes to obesity- and statin-associated hyperglycemia. Cell Reports, 40(8), 111259. https://doi.org/10.1016/j.celrep.2022.111259

Pal, I., Grilo, A. M. S., Gaspary, A., Das Sharma, S., Scotto, L., O’Connor, O. A., Jovanovic, M., Deng, C., & Berchowitz, L. E. (2022). Inhibition of casein kinase 1δ disrupts translation initiation and exerts potent antilymphoma activity. Blood Advances, 6(14), 4157–4161. https://doi.org/10.1182/bloodadvances.2021006833

Briasoulis, A., Doulamis, I., Duque, E. R., Alvarez, P., & Kampaltsis, P. (2022). Early Mammalian Target of Rapamycin Inhibitor Utilization After Heart Transplantation: Analysis of the UNOS Database. The Journal of Heart and Lung Transplantation, 41(4), S455. https://doi.org/10.1016/j.healun.2022.01.1149